Moderna, Inc. MRNA
198.88
4.06
2.08%
as of 25 Sep
- Market cap
- $78.8B
- P/E
- 0.0×
Follow MRNA
Indexes
indicate stock being part of an index
Moderna, Inc. (MRNA) Revenue growth
Moderna, Inc.'s revenue growth over the twelve months to 30 June 2026 was −27.6%, up 12.3 percentage points from fiscal 2025 (−39.9%). Over the past ten years it has ranged from −64.5% (fiscal 2023) to 2,200.3% (fiscal 2021); the current reading is higher than 50% of that period. That is below the Biotechnology industry median of 5.64% and below the Healthcare sector median of 8.26%.
Revenue growth, annual
Annual
| Period | Revenue growth | Change (points) |
|---|---|---|
| FY2025 | −39.9% | 12.82 |
| FY2024 | −52.8% | 11.70 |
| FY2023 | −64.5% | (68.74) |
| FY2022 | 4.29% | (2,195.96) |
| FY2021 | 2,200.3% | 961.92 |
| FY2020 | 1,238.3% | 1,293.91 |
| FY2019 | −55.6% | (21.20) |
| FY2018 | −34.4% | (124.26) |
| FY2017 | 89.9% | 137.26 |
| FY2016 | −47.4% | — |
Quarterly
| Period | Revenue growth | Change (points) |
|---|---|---|
| Jun 2026 | 2.11% | (258.08) |
| Mar 2026 | 260.2% | 290.00 |
| Dec 2025 | −29.8% | 15.63 |
| Sep 2025 | −45.4% | (4.36) |
| 30 more quarters | Free account |
Against its own ten years
Low −64.5%
High 2,200.3%
Ten-year median
−37.2%
Current reading's percentile
50
Revenue growth against peers
| Company | Revenue growth |
|---|---|
| INSM Insmed, Inc. compare | 185.8% |
| ALNY Alnylam Pharmaceuticals, Inc. compare | 95.1% |
| ARGX argenex SE compare | 70.6% |
| ONC BeOne Medicines Ltd. - Sponsored ADR compare | 34.4% |
| VRTX Vertex Pharmaceuticals Incorporated compare | 10.2% |
| RPRX Royalty Pharma PLC compare | 10.0% |
| REGN Regeneron Pharmaceuticals, Inc. compare | 9.29% |
| RVMD Revolution Medicines, Inc. compare | −8.81% |
| MRNA Moderna, Inc. | −27.6% |
| Biotechnology industry median | 5.64% |
| Healthcare sector median | 8.26% |
| Market median | 7.41% |
What Revenue growth is
Revenue Growth shows how fast a company’s sales are rising or falling compared with the same period a year earlier.
(Revenue − Revenue a year earlier) ÷ |Revenue a year earlier|
More on MRNA
- Revenue
- Net income
- EBITDA
- Free cash flow
- Operating cash flow
- Gross margin
- Operating margin
- Net margin
- Free cash flow margin
- P/E ratio
- P/S ratio
- P/B ratio
- Price to free cash flow
- EV/EBITDA
- EV/Sales
- Return on equity
- Return on assets
- Return on invested capital
- Debt to equity
- Current ratio
- Total debt
- Shares outstanding
- Book value per share
- The full statement